Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
Holding AXSM?
Track your performance easily
AXSM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$61.14 - $105.00
Previous Close$98.68
Volume665.74K
Average Volume (3M)469.26K
Market Cap
$4.78B
Enterprise Value$4.65B
Total Cash (Recent Filing)$327.34M
Total Debt (Recent Filing)$191.02M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Mar 03, 2025EPS Estimate
-$0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.54
Shares Outstanding48,462,376
10 Day Avg. Volume750,220
30 Day Avg. Volume469,260
Standard Deviation0.31
R-Squared0.04
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)49.27
Price to Sales (P/S)13.67
Price to Cash Flow (P/CF)-62.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue13.73
Enterprise Value/Gross Profit19.00
Enterprise Value/Ebitda-15.88
Forecast
1Y Price Target
$135.15Price Target Upside38.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Axsome Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsManagement indicated that both Phase 3 (ADVANCE-2 and ACCORD-2) trials for AD-A are fully enrolled, with a successful outcome considered more likely than not, promising potential advancements in treatment options.
EarningsAXSM reported better than expected results with net Auvelity product sales that came in 7%/6% higher than estimates, demonstrating strong financial performance.
Market ExpansionAn increase in Auvelity's commercial payor coverage to 78% of covered lives from the prior 60% signifies a substantial enhancement in market reach and accessibility.
Bears Say
Financial PerformanceAuvelity's performance came in below that of the antidepressant analogs that are tracked.
Market CompetitionPotential emerging competition from novel kappa opioid receptor antagonists being developed by Neumora Therapeutics and Johnson & Johnson.
Pipeline RiskIf ADVANCE-2 fails, the stock could decline significantly, raising doubts about AXSM's ability to execute on its pipeline.
---
Ownership Overview
1.40% Insiders
18.09% Mutual Funds
40.35% Other Institutional Investors
27.08% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AXSM FAQ
What was Axsome Therapeutics Inc’s price range in the past 12 months?
Axsome Therapeutics Inc lowest stock price was $61.14 and its highest was $105.00 in the past 12 months.
What is Axsome Therapeutics Inc’s market cap?
Currently, no data Available
When is Axsome Therapeutics Inc’s upcoming earnings report date?
Axsome Therapeutics Inc’s upcoming earnings report date is Mar 03, 2025 which is in 97 days.
How were Axsome Therapeutics Inc’s earnings last quarter?
Axsome Therapeutics Inc released its earnings results on Nov 12, 2024. The company reported -$1.34 earnings per share for the quarter, beating the consensus estimate of -$1.383 by $0.043.
Is Axsome Therapeutics Inc overvalued?
According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued.
Does Axsome Therapeutics Inc pay dividends?
Axsome Therapeutics Inc does not currently pay dividends.
What is Axsome Therapeutics Inc’s EPS estimate?
Axsome Therapeutics Inc’s EPS estimate is -$0.96.
How many shares outstanding does Axsome Therapeutics Inc have?
Axsome Therapeutics Inc has 48,462,376 shares outstanding.
What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?
Axsome Therapeutics Inc reported an EPS of -$1.34 in its last earnings report, beating expectations of -$1.383. Following the earnings report the stock price went up 9.354%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc?
Among the largest hedge funds holding Axsome Therapeutics Inc’s share is Fairmount Funds Management Llc. It holds Axsome Therapeutics Inc’s shares valued at 212M.
---
Axsome Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$135.15 (38.62% Upside)
$135.15 (38.62% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 571.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
64.19%
12-Months-Change
Fundamentals
Return on Equity
-171.61%
Trailing 12-Months
Asset Growth
-6.56%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
---
AXSM Company Deck
---
AXSM Earnings Call
Q3 2024
0:00 / 0:00
---
AXSM Stock 12 Month Forecast
Average Price Target
$135.15
▲(38.62% Upside)
Technical Analysis
Best Analysts Covering AXSM
1 Year
1 Year Success Rate
16/17 ratings generated profit
1 Year Average Return
+49.51%
reiterated a buy rating 13 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 94.12% of your transactions generating a profit, with an average return of +49.51% per trade.
---